Jean-Claude Tardif
Jean-Claude Tardif (born in 1964) is the Director of the Research Center at the Montreal Heart Institute and Professor of Medicine at the University of Montreal. He received his medical degree (MD) in 1987 from the University of Montreal and specialized in cardiology and research in Montreal and Boston until 1994. Dr. Tardif holds the Canada Research Chair in personalized medicine and the University of Montreal endowed research chair in atherosclerosis. He is also the Scientific Director of the Montreal Health Innovations Coordinating Center (MHICC).His research covers the molecular and genomic aspects of atherosclerosis and related diseases and also involves animal models, mechanistic and observational clinical studies as well as early clinical trials and large international randomized clinical trials. Dr. Tardif is or has been the international principal investigator or part of the study leadership of several large clinical trials in the field of atherosclerosis and other cardiovascular diseases. Dr. Tardif and his team have created the Beaulieu-Saucier Pharmacogenomics Center at the Montreal Heart Institute and he has created the Center of Excellence in Personalized Medicine, the latter funded by the Network of Centers of Excellence of Canada and which has also been supported by multiple pharmaceutical and biotechnological companies.
Dr. Tardif has authored more than 750 scientific articles and has won multiple awards, including the Research Achievement Award of the Canadian Cardiovascular Society, the Distinguished Lecturer Award of the Canadian Institutes for Health Research, the Genesis Award of BIOQuébec (for his outstanding contributions to life sciences), the Armand-Frappier Award of the Government of Québec (the highest scientific honour) and the Margolese National Heart Disorders Prize (for his outstanding contributions to the treatment, amelioration, or cure of heart disorders). Because of his accomplishments, Dr. Tardif was named Fellow of the Canadian Academy of Health Sciences and Fellow of the Royal Society of Canada and was inducted in the Order of Canada (the highest distinction in the country). Provided by Wikipedia
Showing 1 - 20 results of 62 for search 'Jean-Claude Tardif', query time: 0.06s
Refine Results
-
1
-
2
-
3
-
4
-
5
-
6
-
7
-
8
Fabricating Water Dispersible Superparamagnetic Iron Oxide Nanoparticles for Biomedical Applications through Ligand Exchange and Direct Conjugation by Tina Lam, Pramod K. Avti, Philippe Pouliot, Foued Maafi, Jean-Claude Tardif, Éric Rhéaume, Frédéric Lesage, Ashok Kakkar
Published 2016-05-01
Article -
9
Knockdown of ANGPTL2 promotes left ventricular systolic dysfunction by upregulation of NOX4 in mice by Pauline Labbé, Pauline Labbé, Cécile Martel, Cécile Martel, Yan-Fen Shi, Augusto Montezano, Ying He, Marc-Antoine Gillis, Marie-Ève Higgins, Louis Villeneuve, Rhian Touyz, Jean-Claude Tardif, Jean-Claude Tardif, Nathalie Thorin-Trescases, Eric Thorin, Eric Thorin, Eric Thorin
Published 2024-02-01
Article -
10
-
11
-
12
-
13
Use of Anticoagulants and Antiplatelet Agents in Stable Outpatients with Coronary Artery Disease and Atrial Fibrillation. International CLARIFY Registry. by Laurent Fauchier, Nicola Greenlaw, Roberto Ferrari, Ian Ford, Kim M Fox, Jean-Claude Tardif, Michal Tendera, Ph Gabriel Steg, CLARIFY Investigators
Published 2015-01-01
Article -
14
-
15
Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. by Mary P McGowan, Jean-Claude Tardif, Richard Ceska, Lesley J Burgess, Handrean Soran, Ioanna Gouni-Berthold, Gilbert Wagener, Scott Chasan-Taber
Published 2012-01-01
Article -
16
Leveraging large observational studies to discover genetic determinants of drug concentrations: A proof‐of‐concept study by Maxime Meloche, Grégoire Leclair, Martin Jutras, Essaïd Oussaïd, Marie‐Josée Gaulin, Ian Mongrain, David Busseuil, Jean‐Claude Tardif, Marie‐Pierre Dubé, Simon deDenus
Published 2022-04-01
Article -
17
-
18
Circulating levels of linoleic acid and HDL-cholesterol are major determinants of 4-hydroxynonenal protein adducts in patients with heart failure by Caroline Asselin, Anique Ducharme, Thierry Ntimbane, Matthieu Ruiz, Annik Fortier, Marie-Claude Guertin, Joël Lavoie, Ariel Diaz, Émile Levy, Jean-Claude Tardif, Christine Des Rosiers
Published 2014-01-01
Article -
19
Population Pharmacokinetics of Candesartan in Patients with Chronic Heart Failure by Imad Kassem, Steven Sanche, Jun Li, Guillaume Bonnefois, Marie‐Pierre Dubé, Jean‐Lucien Rouleau, Jean‐Claude Tardif, Michel White, Jacques Turgeon, Fahima Nekka, Simon deDenus
Published 2021-01-01
Article -
20
Chasing the storm: Recruiting non‐hospitalized patients for a multi‐site randomized controlled trial in the United States during the COVID‐19 pandemic by Kelly Hu, Jean‐Claude Tardif, Melanie Huber, Maria Daly, Aisha T. Langford, Ruth Kirby, Yves Rosenberg, Judith Hochman, Avni Joshi, Zohar Bassevitch, Michael H. Pillinger, Binita Shah
Published 2022-04-01
Article